Co-administration of iRGD enhancing the anticancer efficacy of cisplatin-loaded polypeptide nanopart

• 作 者: HaiyangYu;ZhaohuiTang;WantongSong;DaweiZhang;YingZhang;XuesiChen;
• 机 构: Key Laboratory of Polymer Ecomaterials,Changchun Institute of Applied Chemistry,Chinese Academy of S
• 出 处: The Third Symposium on Innovative Polymers for Controlled De
• 发表日期: 2014年期

　　Nanoparticles mainly remain in the perivascular regions of solid tumors (Dmean<50μm) after iv injection.Therefore,there is a low contact probability for nanoparticles to reach a majority of target cells within a solid tumor.As a result,the therapeutic efficacy of anticancer nanomedicines is limited [1].iRGD can selectively enhance the vascular and tissue permeability of tumors overexpressing αv integrins and neuropilin-1.Consequently,the co-administration of iRGD may have the possibility to enhance the efficacy of anticancer nanomedicine.Herein,we present the treatment of B16F1 melanoma with a combination of cisplatin-loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) nanoparticles (NP2) and iRGD [2].